News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Nitto Denko Corporation (XETRA: ND5.DE) Obtains US Patent for Antifibrotic Therapies with Molecular Targeting DDS Technology


5/10/2012 11:02:14 AM

OSAKA, Japan--(BUSINESS WIRE)--Japan's leading diversified materials manufacturer, Nitto Denko Corporation (TOKYO:6988)(ISIN:JP3684000007), today announced that a basic patent regarding the company's epoch-making antifibrotic therapy has been successfully registered in the USA. Nitto Denko has been developing antifibrotic drugs in collaboration with Professor Yoshiro Niitsu at Sapporo Medical University since 2008, and has already been granted this patent in Japan, China and Australia.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES